Key result
Beta-blockers show no quality-of-life benefit over no therapy post-MI with preserved LVEF.
Why the study?
Contemporary evidence on the effects of beta-blockers on health-related quality of life after MI in patients without heart failure and with LVEF >40% was limited despite widespread use.
Does beta-blocker therapy influence health-related quality of life after myocardial infarction in patients with left ventricular ejection fraction >40%?
RCT (n=2,707)
Open-label
randomised
Does beta-blocker therapy influence health-related quality of life after myocardial infarction in patients with left ventricular ejection fraction >40%?
Beta-blocker therapy does not negatively or positively impact health-related quality of life over 24 months in patients following myocardial infarction with preserved or mildly reduced ejection fraction (LVEF >40%).
Answers are grounded in this paper and cite their sources.
Beta-blockers can be omitted without QoL impact in post-MI LVEF >40% patients; confirms neutral effect on HRQoL in this RCT population.
BACKGROUND AND AIMS: Contemporary evidence on the effects of beta-blockers on health-related quality of life (HRQoL) after myocardial infarction (MI) in patients without heart failure is limited, despite widespread use. In this prespecified substudy of the DANBLOCK trial, we aimed to assess whether beta-blocker therapy influences HRQoL after MI in patients with left ventricular ejection fraction (LVEF) >40%. METHODS: Patients with a recent (≤14 days) MI and LVEF >40% were randomised to open-label beta-blocker therapy or no beta-blocker. HRQoL was assessed at baseline and at three-, 12-, and 24-months using the EQ-5D-5L questionnaire and the EQ visual analogue scale (EQ VAS). The primary endpoints were between-group differences in change from baseline to each follow-up visit estimated by a linear mixed-effects model. RESULTS: Among 2707 randomised patients, 2681 (99%) completed at least one EQ-5D-5L questionnaire. Median EQ-5D and EQ VAS scores at baseline were 0.95 (Interquartile range [IQR]: 0.87-1.00) and 77 (IQR: 65-87), respectively. Scores remained stable throughout follow-up. No significant between-group differences for EQ-5D index score and EQ VAS score were observed at any time point. At 12 months, mean difference (beta-blocker minus no beta-blocker) in EQ-5D index- and EQ VAS score was -0.001 (95% confidence interval [CI], -0.016 to 0.013, P=0.86) and -1.35 (95% CI, -2.85 to 0.15, P=0.08), respectively. Results were consistent in prespecified subgroups (age, sex, type of MI, and LVEF). CONCLUSION: Overall, a high HRQoL was observed among post-MI patients. Beta-blocker therapy did not affect HRQoL after MI in patients without heart failure.
No takes yet. Share an insight, caveat, or question.
Rykind et al. (2026) conducted an RCT in Myocardial infarction without heart failure (LVEF >40%) (n=2,707). Beta-blocker therapy vs. No beta-blocker was evaluated on Between-group differences in change from baseline to each follow-up visit in EQ-5D-5L index score and EQ VAS score (MD -0.001, 95% CI -0.016 to 0.013, p=0.86). Beta-blocker therapy did not affect health-related quality of life at 12 months compared to no beta-blocker in post-MI patients with LVEF >40%.
Synapse has enriched 10 related papers. Consider them for comparative context: